Kwality Pharmaceuticals Ltd

Kwality Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kwality Pharmaceuticals Ltd

₹ 940 -1.60%
21 May 10:10 a.m.
kwalitypharma.com BSE: 539997
About

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]

Key Points

Business Overview:[1][2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations

Website BSE
  • Market Cap ₹ 975 Cr.
  • Current Price ₹ 940
  • High / Low ₹ 1,070 / 481
  • Stock P/E 24.5
  • Book Value ₹ 254
  • Dividend Yield 0.00 %
  • ROCE 18.4 %
  • ROE 16.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 15.5%
  • Company's median sales growth is 22.4% of last 10 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 152 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
64 70 56 56 69 67 70 78 92 80 90 84 116
48 52 40 41 57 54 54 61 71 63 70 67 90
Operating Profit 16 18 16 15 11 14 15 17 21 17 20 18 26
OPM % 25% 26% 28% 27% 17% 20% 22% 21% 22% 22% 22% 21% 22%
2 0 1 0 -15 0 0 1 -7 0 0 1 1
Interest 1 1 1 2 2 2 2 3 3 2 3 2 2
Depreciation 3 3 4 4 4 5 5 5 5 4 5 5 5
Profit before tax 14 14 12 10 -10 7 8 10 6 11 13 11 19
Tax % 25% 25% 19% 28% -24% 25% 24% 21% 29% 25% 33% 25% 24%
10 11 9 7 -7 5 6 8 4 8 8 9 14
EPS in Rs 10.12 10.16 9.08 6.84 -7.11 5.22 6.01 7.41 4.20 8.06 8.16 8.22 13.96
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
60 52 74 98 137 166 139 262 456 251 307 370
56 49 69 89 126 150 125 233 285 190 241 290
Operating Profit 4 3 5 9 12 16 14 29 172 61 66 80
OPM % 6% 6% 7% 9% 8% 9% 10% 11% 38% 24% 22% 22%
0 0 0 1 1 1 4 2 4 -14 -5 2
Interest 1 1 1 2 2 2 3 3 3 7 10 10
Depreciation 1 1 2 3 3 3 4 6 11 15 20 18
Profit before tax 2 1 2 6 7 11 11 21 162 26 31 54
Tax % 47% 41% 48% 42% 39% 31% 25% 30% 26% 25% 24% 26%
1 1 1 3 4 8 8 15 120 19 24 40
EPS in Rs 0.93 0.92 1.55 3.23 4.39 7.28 8.02 14.60 115.64 18.67 22.94 38.41
Dividend Payout % 0% 0% 0% 9% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 22%
5 Years: 22%
3 Years: -7%
TTM: 21%
Compounded Profit Growth
10 Years: 48%
5 Years: 37%
3 Years: -31%
TTM: 38%
Stock Price CAGR
10 Years: %
5 Years: 92%
3 Years: 36%
1 Year: 89%
Return on Equity
10 Years: 27%
5 Years: 29%
3 Years: 15%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 4 4 5 5 10 10 10 10 10 10 10 10
Reserves 13 15 17 20 19 27 36 51 171 190 214 254
6 8 13 19 26 29 35 41 54 90 98 112
12 10 17 26 40 39 52 64 105 70 72 71
Total Liabilities 35 37 51 71 96 105 133 166 341 361 394 447
13 13 13 17 20 29 43 57 92 120 139 146
CWIP 0 0 0 0 0 0 0 3 12 14 0 0
Investments 1 1 2 4 5 5 4 5 0 0 0 0
22 24 37 50 70 71 86 102 237 226 255 302
Total Assets 35 37 51 71 96 105 133 166 341 361 394 447

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-1 1 -3 4 -1 14 6 27 61 41 43 53
-3 -1 -2 -7 -6 -12 -18 -23 -63 -48 -26 -29
3 1 6 5 5 -2 12 1 6 1 -17 -14
Net Cash Flow -1 1 0 2 -1 -0 0 4 3 -6 -1 10

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 41 63 89 84 98 84 79 50 55 104 136 152
Inventory Days 58 61 67 71 54 34 94 38 97 310 187 167
Days Payable 58 40 63 65 80 52 96 58 63 117 106 112
Cash Conversion Cycle 42 85 93 90 73 67 77 30 90 297 217 208
Working Capital Days 61 81 89 76 74 61 99 47 87 209 194 194
ROCE % 9% 13% 19% 19% 22% 18% 26% 98% 19% 16% 18%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
54.45% 54.44% 54.44% 54.73% 54.73% 54.76% 54.76% 54.82% 54.82% 54.82% 54.82% 54.82%
0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.02% 0.03% 0.32%
45.55% 45.56% 45.54% 45.25% 45.25% 45.22% 45.22% 45.17% 45.18% 45.15% 45.14% 44.86%
No. of Shareholders 1,0494,1985,3766,2116,9436,2915,7865,6955,2737,4878,9479,420

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • May 2024
    Transcript
    Notes
    PPT
  • May 2024
    Transcript
    Notes
    PPT
  • Aug 2023
    Transcript
    Notes
    PPT
  • May 2022
    Transcript
    Notes
    PPT